<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gonzalez-Gonzalez A</submitter><funding>Secretaria de Investigacion y Posgrado from Instituto Politecnico Nacional</funding><funding>Programa de Recursos Fiscales para Investigación from Instituto Nacional de Pediatría</funding><pagination>2413018</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11523249</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(1)</volume><pubmed_abstract>In this study, n-butyl and iso-butyl quinoxaline-7-carboxylate-1,4-di-&lt;i>N&lt;/i>-oxide derivatives were evaluated &lt;i>in vitro&lt;/i> against &lt;i>Giardia lamblia&lt;/i> (&lt;i>G. lamblia&lt;/i>)&lt;i>, Trichomonas vaginalis&lt;/i> (&lt;i>T. vaginalis&lt;/i>), and &lt;i>Entamoeba histolytica&lt;/i> (&lt;i>E. histolytica&lt;/i>). The potential mechanism of action determination was approached by &lt;i>in silico&lt;/i> analysis on &lt;i>G. lamblia&lt;/i> and &lt;i>T. vaginalis&lt;/i> triosephosphate isomerase (&lt;i>Gl&lt;/i>TIM and &lt;i>Tv&lt;/i>TIM, respectively), and on &lt;i>E. histolytica&lt;/i> thioredoxin reductase (&lt;i>EhTrxR&lt;/i>). Enzyme inactivation assays were performed on recombinant G&lt;i>l&lt;/i>TIM and &lt;i>Eh&lt;/i>TrxR. Compound T-167 showed the best giardicidal activity (IC&lt;sub>50&lt;/sub> = 25.53 nM) and the highest inactivation efficiency against G&lt;i>l&lt;/i>TIM w</pubmed_abstract><journal>Journal of enzyme inhibition and medicinal chemistry</journal><pubmed_title>Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-&lt;i>N&lt;/i>-oxide derivatives against &lt;i>Giardia lamblia&lt;/i>, &lt;i>Trichomonas vaginalis&lt;/i>, and &lt;i>Entamoeba histolytica.&lt;/i> An &lt;i>in vitro&lt;/i> and &lt;i>in silico&lt;/i> approach.</pubmed_title><pmcid>PMC11523249</pmcid><funding_grant_id>SIP-20240460</funding_grant_id><funding_grant_id>SIP-20230935</funding_grant_id><funding_grant_id>2019/062</funding_grant_id><pubmed_authors>Delgado-Maldonado T</pubmed_authors><pubmed_authors>Paz-Gonzalez A</pubmed_authors><pubmed_authors>Lopez-Velazquez G</pubmed_authors><pubmed_authors>Sanchez-Sanchez O</pubmed_authors><pubmed_authors>Ortiz-Perez E</pubmed_authors><pubmed_authors>Yepez-Mulia L</pubmed_authors><pubmed_authors>Rivera G</pubmed_authors><pubmed_authors>Moreno-Rodriguez A</pubmed_authors><pubmed_authors>de la Mora-de la Mora JI</pubmed_authors><pubmed_authors>Arias D</pubmed_authors><pubmed_authors>Vazquez-Jimenez LK</pubmed_authors><pubmed_authors>Chino-Rios L</pubmed_authors><pubmed_authors>Gonzalez-Gonzalez A</pubmed_authors><pubmed_authors>Pacheco-Gutierrez S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-&lt;i>N&lt;/i>-oxide derivatives against &lt;i>Giardia lamblia&lt;/i>, &lt;i>Trichomonas vaginalis&lt;/i>, and &lt;i>Entamoeba histolytica.&lt;/i> An &lt;i>in vitro&lt;/i> and &lt;i>in silico&lt;/i> approach.</name><description>In this study, n-butyl and iso-butyl quinoxaline-7-carboxylate-1,4-di-&lt;i>N&lt;/i>-oxide derivatives were evaluated &lt;i>in vitro&lt;/i> against &lt;i>Giardia lamblia&lt;/i> (&lt;i>G. lamblia&lt;/i>)&lt;i>, Trichomonas vaginalis&lt;/i> (&lt;i>T. vaginalis&lt;/i>), and &lt;i>Entamoeba histolytica&lt;/i> (&lt;i>E. histolytica&lt;/i>). The potential mechanism of action determination was approached by &lt;i>in silico&lt;/i> analysis on &lt;i>G. lamblia&lt;/i> and &lt;i>T. vaginalis&lt;/i> triosephosphate isomerase (&lt;i>Gl&lt;/i>TIM and &lt;i>Tv&lt;/i>TIM, respectively), and on &lt;i>E. histolytica&lt;/i> thioredoxin reductase (&lt;i>EhTrxR&lt;/i>). Enzyme inactivation assays were performed on recombinant G&lt;i>l&lt;/i>TIM and &lt;i>Eh&lt;/i>TrxR. Compound T-167 showed the best giardicidal activity (IC&lt;sub>50&lt;/sub> = 25.53 nM) and the highest inactivation efficiency against G&lt;i>l&lt;/i>TIM w</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2026-06-02T22:14:01.752Z</modification><creation>2025-04-06T14:25:08.995Z</creation></dates><accession>S-EPMC11523249</accession><cross_references><pubmed>39470324</pubmed><doi>10.1080/14756366.2024.2413018</doi></cross_references></HashMap>